

Appln No.: 10/605,498
Amendment Dated: April 20, 2005
Reply to Office Action of March 23, 2005

REMARKS/ARGUMENTS

Responsive to the Restriction Requirement for the above-referenced application, Applicants hereby elect the invention of claims 14-24, and Seq. ID No. 82 for initial examination in this application. Claims 14-17 are generic, and claim 19 is specific to the elected invention.


Applicants have amended claims 1 and 14 to refer to therapeutics that are oligonucleotides. Although not elected, claim 1 has been amended to conform to the scope of claim 14 so that the recombination referenced by the Examiner would remain appropriate.

Claims 25-28 have been added, and the fee for four additional dependent claims is enclosed. The Commissioner is authorized to charge any additional fees or Credit any overpayment to Deposit Account No. 15-0610.

Support for claims 25-28 is found in paragraph 0005.

The abstract has been amended to delete a header that was inadvertently included during electronic filing.

Respectfully submitted,



Marina T. Larson Ph.D.
PTO Reg. No. 32,038
Attorney for Applicant
(970) 468-6600

Enclosure

Credit Card Payment Form